OBJECTIVE: This study investigated the role of a @entity134 pretreatment on the pregnancy rate and pregnancy outcomes in @entity1 positive for antithyroid antibodies who were undergoing induction of ovulation and intrauterine insemination (IUI). METHODS: A double-blind, randomized, prospective cohort study was conducted on @entity249 @entity1 who met the following criteria: @entity249 for >=  1 year, age 20-38 years, no more than 2 previous assisted reproduction treatment cycles, regular spontaneous menstrual cycles, no treatments 1 month before recruitment, normal uterine cavity, and bilateral tubal patency. The @entity1 were divided into 2 groups: a study group of @entity249 women with antithyroid autoimmunity (radioimmunoassay positive with titer >100 U/mL) and a control group of @entity249 women without antithyroid autoimmunity. The patients with antithyroid autoimmunity were randomly assigned in a blinded manner to an intervention group treated with @entity229 (administered orally for 4 weeks before IUI) or a group given matching placebo. The primary objective was to compare the pregnancy and miscarriage rates among all 3 the groups. RESULTS: The study included 98 @entity249 @entity1 : 48 with antithyroid autoimmunity (antibody positive) and 50 without antithyroid autoimmunity (antibody negative). The study groups were comparable for baseline characteristics (age, race, body mass index, hormonal pattern, number of smokers, previous miscarriage). In the antithyroid antibody-positive group, the pregnancy rate was 33.3% (8/24) among @entity1 treated with @entity229 compared with 8.4% (2/24) among @entity1 who received placebo (odds ratio [OR] = 5.5; 95% CI, 1.13-25.76; P = 0.03). In the antibody-negative group, the pregnancy rate was 8.0% (4/50). Among the pregnancies, the miscarriage rate was 70% (7/10) versus 75% (3/4) for @entity1 with or without antithyroid antibodies, respectively (P = NS); the miscarriage rate was 75% (6/8) for @entity1 treated with @entity229 versus 50% (1/2) for @entity1 taking placebo (P = 0.49). No adverse effects were reported. CONCLUSIONS: In this small cohort study of @entity249 women with antithyroid antibodies undergoing induction of ovulation and IUI, prophylactic therapy with @entity229 was associated with a significantly higher rate of pregnancy compared with placebo. The miscarriage rate was not significantly different among the 3 groups.

Preconception @entity134 treatment in XXXX women with antithyroid autoimmunity undergoing ovarian stimulation and intrauterine insemination: a double-blind, randomized, prospective cohort study.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility', 'infertile'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']
@entity249 :: (MESH:D007246,Disease) :: ['infertile']
